C. Wright

TL;DR: Lymph node, epidermal growth factor receptor, and estrogen receptor status, tumor size, and histological grade also had prognostic significance but, applying multivariate analysis, only lymph node status was a more important predictor of relapse-free and overall survival than staining for the c-erbB-2 oncoprotein.

TL;DR: It is suggested that c-erbB-2 protein overexpression, a marker of poor prognosis in breast cancer, is associated with a lack of response to endocrine therapy on relapse, and particularly in combination with EGFR may be useful in directing therapeutic choices.

TL;DR: There was an increased risk of relapse and death associated with c-erbB-2 expression irrespective of nodal involvement and this marker thus appears to be a significant prognostic factor in the early as well as the late stages of breast cancer.

TL;DR: The data suggest p53 protein expression may be a marker of more aggressive carcinomas but that the prognostic power of expression is likely to be weak and unlikely, therefore, to be of clinical value.

TL;DR: Epidermal growth factor receptors (EGFRs) were measured in 221 primary breast cancers by ligand binding with 125I-labelled EGF, and high-affinity sites were quantitated, and expression of neu conferred similar poor prognosis to EGFR expression in all prognostic subgroups.